BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced initial dosing in a Phase 1 trial of EDG-7500.
Researchers at the University of California, Irvine, have developed a polymeric biohybrid cardiac device that harnesses the ...
When a muscle contracts, the parts of a sarcomere "shorten" and come closer together. Each cardiac muscle cell can have over 5,000 sarcomeres, which compounds both the shortening and relaxation events ...
Hierarchical structure of muscle and activation of thin filaments. In both skeletal and cardiac muscles under a relaxed state, a low intracellular calcium ion concentration is maintained and the ...
Researchers have investigated the effect of increased cell temperature on the contractility of skeletal muscle and cardiac muscle by heating the muscle proteins using advanced microscopical techniques ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results